Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a strong player in the regenerative medicine sector, with a diverse portfolio of advanced wound care and sports medicine products. While changes in reimbursement policies and competition pose challenges, ORGO's success in clinical studies and recent positive results for ReNu show their potential for growth. Their efforts to address billing concerns and improve revenue through a wastage reduction program demonstrate a proactive approach to overcoming market challenges.

Bears say

Organogenesis Holdings is currently facing challenges in the advanced wound care market due to a decline in pricing, which is expected to result in a significant decline in the first quarter of 2026. While the company has a strong portfolio and is already seeing improvements in unit volumes, it may take longer for the market to normalize and fully understand the impact of the updated wastage policy. Despite a Buy rating and a $9 PT, the company's performance has been mixed and may improve as it achieves milestone progress and potential market consolidation occurs.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.